Zacks: Brokerages Expect Proteon Therapeutics Inc (NASDAQ:PRTO) to Post -$0.13 Earnings Per Share

Equities research analysts forecast that Proteon Therapeutics Inc (NASDAQ:PRTO) will report ($0.13) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Proteon Therapeutics’ earnings. Proteon Therapeutics posted earnings per share of ($0.28) during the same quarter last year, which would suggest a positive year-over-year growth rate of 53.6%. The business is expected to announce its next earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Proteon Therapeutics will report full-year earnings of ($0.59) per share for the current year. For the next year, analysts expect that the company will post earnings of ($0.18) per share. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Proteon Therapeutics.

Proteon Therapeutics (NASDAQ:PRTO) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.11).

Several research firms recently weighed in on PRTO. JMP Securities lowered shares of Proteon Therapeutics to a “market perform” rating in a research note on Thursday, March 28th. Cowen reiterated a “hold” rating on shares of Proteon Therapeutics in a research note on Wednesday, May 8th. Maxim Group lowered shares of Proteon Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. HC Wainwright increased their price objective on shares of Proteon Therapeutics from $3.00 to $4.00 and gave the stock a “positive” rating in a research note on Monday, March 18th. Finally, Zacks Investment Research upgraded shares of Proteon Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, February 28th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Proteon Therapeutics currently has an average rating of “Hold” and a consensus price target of $2.63.

Several large investors have recently made changes to their positions in the business. Renaissance Technologies LLC increased its stake in shares of Proteon Therapeutics by 43.0% in the first quarter. Renaissance Technologies LLC now owns 455,744 shares of the biopharmaceutical company’s stock valued at $229,000 after purchasing an additional 137,125 shares during the period. Wedbush Securities Inc. acquired a new stake in shares of Proteon Therapeutics in the first quarter valued at approximately $30,000. New Leaf Venture Partners L.L.C. increased its stake in shares of Proteon Therapeutics by 1.5% in the fourth quarter. New Leaf Venture Partners L.L.C. now owns 1,523,200 shares of the biopharmaceutical company’s stock valued at $3,458,000 after purchasing an additional 23,200 shares during the period. Vanguard Group Inc increased its stake in shares of Proteon Therapeutics by 45.9% in the third quarter. Vanguard Group Inc now owns 209,383 shares of the biopharmaceutical company’s stock valued at $408,000 after purchasing an additional 65,833 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Proteon Therapeutics by 45.9% in the third quarter. Vanguard Group Inc. now owns 209,383 shares of the biopharmaceutical company’s stock valued at $408,000 after purchasing an additional 65,833 shares during the period. Institutional investors own 22.86% of the company’s stock.

PRTO remained flat at $$0.40 on Wednesday. 471,938 shares of the company traded hands, compared to its average volume of 1,082,437. The firm has a market capitalization of $8.01 million, a price-to-earnings ratio of -0.35 and a beta of 0.45. Proteon Therapeutics has a 52-week low of $0.35 and a 52-week high of $3.94.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes.

Featured Article: What is a resistance level?

Get a free copy of the Zacks research report on Proteon Therapeutics (PRTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.